These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16762173)

  • 1. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
    Faggioli P; Giani L; Mazzone A
    Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy: a pilot study.
    Shah P; Murray AK; Moore TL; Herrick AL
    J Rheumatol; 2011 Sep; 38(9):2079-80. PubMed ID: 21885525
    [No Abstract]   [Full Text] [Related]  

  • 3. Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study.
    Cutolo M; Ferrone C; Pizzorni C; Soldano S; Seriolo B; Sulli A
    J Rheumatol; 2010 Jun; 37(6):1174-80. PubMed ID: 20436070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasospasmolytic therapy in patients with SSC.
    Jünger M; Schlez A; Klyscz T; Steins A; Hahn M
    Adv Exp Med Biol; 1999; 455():305-7. PubMed ID: 10599360
    [No Abstract]   [Full Text] [Related]  

  • 6. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost.
    Foti C; Cassano N; Conserva A; Coviello C; De Meo M; Vena GA
    Clin Exp Dermatol; 2004 May; 29(3):321-3. PubMed ID: 15115528
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raynaud's of the gut? Systemic sclerosis-associated microvascular ischaemic colitis responsive to intravenous iloprost.
    Pratap K; Penglase R; Roper E; Stoita A
    Rheumatology (Oxford); 2024 Aug; 63(8):e219-e221. PubMed ID: 38290764
    [No Abstract]   [Full Text] [Related]  

  • 10. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical images: iloprost-induced vascular remodeling.
    Pyrpasopoulou A; Aslanidis S
    Arthritis Rheum; 2007 Jul; 56(7):2243. PubMed ID: 17599734
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
    Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
    Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Iloprost therapy in systemic sclerosis].
    Bali G; Aberer E
    Hautarzt; 2003 Sep; 54(9):845-51. PubMed ID: 12955262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
    Trombetta AC; Pizzorni C; Ruaro B; Paolino S; Sulli A; Smith V; Cutolo M
    J Rheumatol; 2016 Nov; 43(11):2033-2041. PubMed ID: 27744392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
    Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
    Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
    Wigley FM; Wise RA; Seibold JR; McCloskey DA; Kujala G; Medsger TA; Steen VD; Varga J; Jimenez S; Mayes M; Clements PJ; Weiner SR; Porter J; Ellman M; Wise C; Kaufman LD; Williams J; Dole W
    Ann Intern Med; 1994 Feb; 120(3):199-206. PubMed ID: 7506013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
    Cutolo M; Zampogna G; Vremis L; Smith V; Pizzorni C; Sulli A
    J Rheumatol; 2013 Jan; 40(1):40-5. PubMed ID: 23118114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.